

Press Release

SYGNIS AG Announces Global Launch of SunScript™ One Step RT-qPCR Kit

- SYGNIS fully executed product launch plan 2015
- 6th consecutive product launch in 2015
- Real-time quantitative transcription and amplification of genomic information in a single step
- Product with highest RT reaction temperature on the market
- Designed for any RNA template
- Available through SYGNIS' global network of distribution partners and SYGNIS online shop

Madrid, Spain and Heidelberg, Germany, January 13, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that it has globally launched the SunScript™ One Step RT-qPCR Kit on December 21, 2015. This product is the third of its SunScript™ product line allowing both transcription and amplification of genomic DNA in a one-step reaction that can be measured at real time. This new kit was developed for a multitude of cutting edge applications like gene expression analysis or microRNA detection, both crucial assays nowadays in oncology and molecular diagnosis research.

SunScript™ One Step RT-qPCR Kit combines SYGNIS' unique high-temperature SunScript™ Reverse Transcriptase with high-quality optimized components in a ready-to-use format that allows every user to obtain real-time quantitative results with high sensitivity and reproducibility.

SunScript™ One Step RT-qPCR Kit has a superior performance in comparison to all competitor kits based on high-temperature RT reactions. Its increased overall specificity and sensitivity even for difficult RNA targets make it the perfect option for any RNA template. In addition, the kit has been designed to be compatible with all qPCR instruments and is optimized for plate format, which makes it suitable for regular research labs and hospitals.

“After signing the latest distribution agreements and the successful completion of our capital increase, we are now happy to announce the last product launch for 2015. With the introduction of our SunScript™ One Step RT-qPCR Kit we are in line with our ambitious product launching plans for 2015 and we are now looking forward to launching more exciting products in 2016 and beyond”, **Pilar de la Huerta, CEO and CFO of SYGNIS** commented. “This expansion of our SunScript™ product line complements our growing portfolio of products with superior features. We are making good progress in establishing ourselves as a leading provider of innovative and superior tools for processing genetic

information for a multitude of applications in fast growing markets such as human genetics, oncology, molecular diagnostics and personalized medicine.”

SunScript™ One Step RT-qPCR Kits are in stock and will be globally commercialized mainly through the Company’s global network of distribution partners as well as the SYGNIS online shop under www.sygnis.com/shop.

For further information please contact:

SYGNIS AG

Pilar de la Huerta
CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com

MC Services AG

Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu

About SYGNIS AG: www.sygnis.com

SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime™ product line and SensiPhi®, licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript™ Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.###